AbbVie Inc

AbbVie insider sale: Crum Demetris D sells 1,594 shares, hinting at portfolio adjustment but not a decline, amid strong pipeline and market‑access strategy.

AbbVie insider buying shows executive confidence, strong earnings, high upside, and a growing oncology pipeline—potentially sparking a short‑term rally.